Abstract
Fibrates are peroxisome proliferator-activated receptor-alpha agonist medications that lower triglycerides. In people with diabetes, fibrates are primarily indicated for severe hypertriglyceridemia (HTG) to reduce pancreatitis risk. Fibrates may also be considered for cardiovascular (CV) protection in those with less severe HTG at high CV risk. Beyond lipid-lowering, fibrates may also delay diabetic retinopathy progression. This population-based cross-sectional study used linked health-care databases held at ICES to examine the incidence and prevalence of fibrate prescriptions in older Ontario adults with diabetes (January 1 to December 31, 2018) and identify predictors of new fibrate prescriptions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
